据了解，作为一家处于商业化阶段的生物制药企业，Apellis致力于发现、开发和商业化治疗未满足医疗 需求的创新疗法。其核心产品线主要包括EMPAVELI和SYFOVRE两大产品：SYFOVRE用于治疗继发于 年龄相关性黄斑变性(GA)的地图样萎缩;而EMPAVELI则用于治疗阵发性睡眠性血红蛋白尿症(PNH)。 分析师特别指出，Apellis与Sobi公司达成的重大特许权购买协议具有战略意义。该协议不仅确保Apellis 可获得最高3亿美元收益(其中包含2.75亿美元首付款)，更将Sobi在Aspaveli销售中的特许权义务削减了 90%。这一举措不仅为Apellis带来即时财务收益，甚至有望缓解投资者对其盈利能力的担忧。 尽管存在这些积极因素，Frommer仍对Apellis的未来发展保持审慎态度。他认为，虽然FDA和CHMP即 将做出的监管决定，以及Empaveli/Aspaveli新适应症的上市都是重大利好，但这些因素在带来市场潜力 的同时，也伴随着同等程度的不确定性。 智通财经APP获悉，摩根士丹利分析师Judah Frommer发表研报，将Apellis Pharmaceuticals(APLS.U ...

Group 1 - The market is highlighting the free cash flow (FCF) potential of Syfovre and Empaveli, with Syfovre projected to exceed $1 billion in annual sales despite initial rollout challenges due to infection reports [1] - The firm faced difficulties in launching Syfovre, but the outlook for its sales remains strong, indicating a recovery in market confidence [1] - A holistic investment approach is emphasized, considering both top-down and bottom-up valuation techniques, with a focus on capital structure and debt covenants impacting equity valuation [1]

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2025 financial results and business highlights. "In the first quarter, we were pleased to see continued growth in SYFOVRE injection demand—a key indicator of long-term market strength—and an increase in share of new patient starts, already reaching 55% in April. However, revenue was impacted by funding shortages at third-party co-pay assistance programs and a larger- than-expected ...